Close
To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked IRAS Number, which will take you to the UCLH Find a Study database.
ELEVATEA Phase 1b/2, Open-label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) | |
|---|---|
| IRAS Number: | 1007543 |
| Principal Investigator | Dr Rebecca Roylance |
| Drug Class/ Treatment: | Elacestrant (Estrogen Receptor Antangonist) + Various Combination |
| Patient Population: | ER+, HER2– Breast Cancer |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
ELECTRA (ELA-0121)A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic | |
|---|---|
| IRAS Number: | 1005373 |
| Principal Investigator | Dr Elisavet Papadimitraki |
| Drug Class/ Treatment: | Elacestrant (Oral selective ER degrader) |
| Patient Population: | Women and men with brain metastasis from estrogen receptor positive, her-2 negative breast cancer |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
PAveMentPhase 1b study of Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer | |
|---|---|
| IRAS Number: | 245336 |
| Principal Investigator: | Dr Rebecca Roylance |
| Drug Class/ Treatment: | Palbociclib (CDK4 and CDK6 Inhibitor) + Avelumab (PD-L1 Monoclonal Antibody) |
| Patient Population: | AR+ Triple Negative Breast Cancer |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
